Antimicrobial cathelicidin polypeptide CAP11 suppresses the production and release of septic mediators in D-galactosamine-sensitized endotoxin shock mice.
Endotoxin shock is a severe systemic inflammatory response that is caused by the augmented production and release of septic mediators. Among them, inflammatory cytokines such as tumor necrosis factor-alpha, IL-1beta and IL-6 play a pivotal role. In addition, anandamide, an endogenous cannabinoid and high-mobility group box-1 (HMGB1), a non-histone chromosomal protein has recently been recognized as members of septic mediators. We previously reported that cationic antibacterial polypeptide of 11-kDa (CAP11), an antimicrobial cathelicidin peptide (originally isolated from guinea pig neutrophils), potently neutralizes the biological activity of LPS and protects mice from lethal endotoxin shock. In this study, to clarify the protective mechanism of CAP11 against endotoxin shock, we evaluated the effects of CAP11 on the production and release of septic mediators in vitro and in vivo using a murine macrophage cell line RAW264.7 and a D-galactosamine-sensitized murine endotoxin shock model. LPS stimulation induced the production of inflammatory cytokines and anandamide and release of HMGB1 from RAW264.7 cells. Importantly, CAP11 suppressed the LPS-induced production and release of these mediators by RAW264.7 cells. Moreover, LPS administration enhanced the serum levels of HMGB1, anandamide and inflammatory cytokines in the endotoxin shock model. Of note, CAP11 suppressed the LPS-induced increase of these mediators in sera, and LPS binding to CD14-positive cells (peritoneal macrophages), accompanied with the increase of survival rates. Together these observations suggest that the protective action of CAP11 on endotoxin shock may be explained by its suppressive effect on the production and release of septic mediators by CD14-positive cells possibly via the inhibition of LPS binding to the targets.
Murakami
Taisuke
T
Department of Host Defense and Biochemical Research, Juntendo University School of Medicine, Tokyo, Japan.
Obata
Toru
T
Kuwahara-Arai
Kyoko
K
Tamura
Hiroshi
H
Hiramatsu
Keiichi
K
Nagaoka
Isao
I
D000818:Animals; D023181:Antimicrobial Cationic Peptides / Q000008:administration & dosage*; D001095:Arachidonic Acids / Q000097:blood / Q000378:metabolism*; D002460:Cell Line; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000097:blood; D015536:Down-Regulation; D063388:Endocannabinoids; D005688:Galactosamine / Q000378:metabolism; D024243:HMGB1 Protein / Q000097:blood / Q000378:metabolism; D007274:Injections, Intraperitoneal; D008070:Lipopolysaccharides / Q000276:immunology; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D053284:Polyunsaturated Alkamides / Q000097:blood / Q000378:metabolism*; D012772:Shock, Septic / Q000097:blood / Q000517:prevention & control*
D023181:Antimicrobial Cationic Peptides; D001095:Arachidonic Acids; C440609:CAP11 protein, Cavia; D016207:Cytokines; D063388:Endocannabinoids; D024243:HMGB1 Protein; D008070:Lipopolysaccharides; D053284:Polyunsaturated Alkamides; D005688:Galactosamine; C078814:anandamide